华泰联合证券有限责任公司关于 广州万孚生物技术股份有限公司部分募投项目重新论证并 暂缓实施的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作 为广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）2022 年度 创业板向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务管理办 法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关规定，对万孚生物部分 募投项目重新论证并暂缓实施情况进行了核查，具体情况如下： 一、募集资金基本情况 | 单位：万元 | | --- | 经中国证券监督管理委员会《关于同意广州万孚生物技术股份有限公司向 特定对象发行股票注册的批复》（证监许可〔2023〕1380 号）同意，公司向特 定对象发行股票 27,450,980 股，每股面值 1.00 元，每股发行价格为 25.50 元， 募集资金总额 699,999,990.00 元，扣除各项发行费用人民币（含税）11,009,741.51 元后，募集资金净额为人民币 688,990,248.49 元。根据立信会计师事务所（特 ...

Core Insights - The fentanyl concept index declined by 0.31%, ranking among the top decliners in the concept sector, with notable declines in stocks such as Botao Bio, Oriental Bio, and Lingrui Pharmaceutical [1][2] - Conversely, three stocks within the sector saw price increases, with Renfu Pharmaceutical, Enhua Pharmaceutical, and China National Pharmaceutical Modern rising by 1.02%, 0.52%, and 0.19% respectively [1][2] Market Performance - The fentanyl concept sector experienced a net inflow of 0.22 billion yuan, despite five stocks facing net outflows, with Oriental Bio leading the outflow at 14.71 million yuan [2] - Other stocks with significant net outflows included China National Pharmaceutical Modern (10.27 million yuan), Wanfu Bio (7.15 million yuan), and Botao Bio (3.49 million yuan) [2] Stock Movements - The top gainers in the fentanyl concept included Renfu Pharmaceutical, China National Pharmaceutical, and Lingrui Pharmaceutical, with net inflows of 42.39 million yuan, 15.59 million yuan, and 2.54 million yuan respectively [2] - The stock performance of Oriental Bio showed a decline of 0.97% with a turnover rate of 1.75%, while Renfu Pharmaceutical had a gain of 1.02% with a turnover rate of 1.51% [2]

北京市君合（广州）律师事务所 关于 广州万孚生物技术股份有限公司 2025 年第二次临时股东大会的 法律意见书 二零二五年十一月 | 北京总部 | 电话: | (86-10) 8519-1300 | 上海分所 | 电话: | (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: | (86-10) 8519-1350 | | 传真: | (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: | (86-571) 2689-8188 | 成都分所 | 电话: | (86-28) 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: | ( ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-067 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 2025 年第二次临时股东大会会议决议公告 一、股东大会的召开和出席情况 广州万孚生物技术股份有限公司（以下简称"公司"）2025 年第二次临时股 东大会于 2025 年 11 月 11 日 14:00 在公司 D 座三楼会议室召开。会议通知已于 2025 年 10 月 27 日在中国证监会指定的信息披露网站公告。本次股东大会由公 司董事会召集，董事长王继华女士主持，公司全体董事、监事、高级管理人员、 公司聘请的见证律师等相关人士出席、列席了本次会议。会议的召集、召开与表 决程序符合《公司法》和《公司章程》的规定。 股东出席情况：通过现场和网络投票的股东 265 人，代表股份 209,117,233 股，占公司有表决权股份总数的 44.7653％。其中： 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更提案 ...

Core Viewpoint - Wanfu Biological (300482.SZ) has conducted a share buyback, acquiring a total of 943,879 shares, which represents 0.20% of the company's total share capital [1] Summary by Categories Share Buyback Details - The share buyback was executed through a dedicated account via centralized bidding transactions [1] - The highest transaction price for the repurchased shares was 21.27 CNY per share, while the lowest was 21.07 CNY per share [1] - The total amount spent on the buyback was 19,984,707.70 CNY, excluding transaction fees [1] Compliance and Regulations - The buyback is in accordance with the company's share repurchase plan and relevant laws and regulations [1]

Core Viewpoint - Wanfu Biological announced a share buyback plan, indicating a commitment to returning value to shareholders and confidence in the company's future performance [1] Summary by Categories Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 943,879 shares, which represents 0.20% of the company's total share capital [1]

Core Points - The fentanyl concept index declined by 1.78% as of the market close on November 3, ranking among the top decliners in the concept sector [1] - Within the fentanyl sector, stocks such as Botao Bio, Enhua Pharmaceutical, and Renfu Pharmaceutical experienced significant declines, while Guoyao Modern and Guoyao Shares saw slight increases of 0.48% and 0.24% respectively [1] Market Performance - The fentanyl concept sector faced a net outflow of 0.38 billion yuan in main capital today, with six stocks experiencing net outflows [2] - Enhua Pharmaceutical led the outflows with a net capital outflow of 15.56 million yuan, followed by Guoyao Shares, Lingrui Pharmaceutical, and Wanfu Biological with outflows of 10.74 million yuan, 9.79 million yuan, and 8.30 million yuan respectively [2] - Conversely, Renfu Pharmaceutical and Botao Bio attracted net inflows of 10.87 million yuan and 1.47 million yuan respectively [2] Stock Performance - Enhua Pharmaceutical saw a decline of 2.10% with a turnover rate of 1.29% and a net outflow of 15.56 million yuan [2] - Guoyao Shares increased by 0.24% with a turnover rate of 1.19% and a net outflow of 10.74 million yuan [2] - Lingrui Pharmaceutical decreased by 0.75% with a turnover rate of 1.22% and a net outflow of 9.79 million yuan [2] - Wanfu Biological declined by 0.82% with a turnover rate of 2.26% and a net outflow of 8.30 million yuan [2] - Botao Bio experienced a significant drop of 8.32% with a turnover rate of 4.20% but had a net inflow of 1.47 million yuan [2] - Renfu Pharmaceutical decreased by 1.94% with a turnover rate of 2.56% and a net inflow of 10.87 million yuan [2]

Group 1 - Company Wanfang Bio announced a stock repurchase plan, with a total of approximately 940,000 shares repurchased, accounting for 0.2% of the company's total share capital [1] - The highest transaction price for the repurchased shares was 21.27 yuan per share, while the lowest was 21.07 yuan per share [1] - The total amount spent on the repurchase was approximately 19.98 million yuan [1]

关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-066 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开的第五届董事会第十四次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式回购公司已发行的人民币普通股股 份，用于员工持股计划和股权激励。本次用于回购股份的资金总额不低于人民币 3,000 万元且不超过人民币 6,000 万元（均包含本数），回购价格不超过人民币 34.66 元/股（含），回购实施期限自公司董事会审议通过本次回购方案之日起 6 个月内。具体内容详见公司刊登在中国证监会指定创业板信息披露网站上的相关 公告。 （二）中国证监会和本所规定的其他情形。 2、公司以集中竞价交易方式回购股份，符合下列要求： 根据《上市公司股份回购规则》《深圳证券交 ...

Core Points - The Bioeconomy Index (970038) closed at 2277.51 points, down 0.16%, with a trading volume of 18.883 billion yuan and a turnover rate of 1.2% [1] - Among the index constituents, 23 stocks rose while 27 fell, with Iwubio leading the gainers at 6.71% and Meiya Optoelectronics leading the decliners at 3.02% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 225.09 yuan, and a market cap of 272.908 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 116.50 yuan, and a market cap of 47.525 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 31.97 yuan, and a market cap of 56.849 billion yuan [1] - Other notable constituents include Shishihistory (sz002252), Table Pharmaceutical (sz300347), and Muyuan Foods (sz002714) [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 871 million yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [3] - Key capital flows include: - Iwubio (300357) with a net inflow of 52.9277 million yuan from institutional investors [3] - Dabo Medical (002901) with a net inflow of 31.8434 million yuan from institutional investors [3] - Changchun High-tech (000661) with a net inflow of 27.6452 million yuan from institutional investors [3]